Opus Genetics, Inc. (IRD)

Every figure this model derived for IRD, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2026-06-30.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 0 PaymentsToAcquirePropertyPlantAndEquipment 2020-12-31
cash 88,812,000 CashAndCashEquivalentsAtCarryingValue 2026-06-30
current assets 92,696,000 AssetsCurrent 2026-06-30
current liabilities 7,605,000 LiabilitiesCurrent 2026-06-30
equity -12,986,000 StockholdersEquity 2026-06-30
interest expense 272,000 InterestExpenseNonoperating 2026-06-30
ocf -40,667,000 NetCashProvidedByUsedInOperatingActivities 2026-06-30
revenue 9,856,000 RevenueFromContractWithCustomerExcludingAssessedTax 2026-06-30
sbc 4,461,000 ShareBasedCompensation 2026-06-30

The ratios

The figures themselves rather than their scores — what somebody looking up IRD on one particular measure came for.

RatioValue
cash operating margin-467.67
current ratio12.19
current ratio reported12.19
deferred revenue growth-56.67
dilution pct133.04
fcf margin-412.61
growth cv2.06
interest cover-186.06
operating margin-513.47
owner earnings margin-457.87
revenue growth-36.09
revenue growth per share-72.57
rule of 40-549.56
sbc pct revenue45.26

What to be careful about

What this model itself distrusts about IRD's figures. Written by the derivation as it ran, not added afterwards.